Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

In the high-vol­ume gener­ics game, size mat­ters — and no one is quite so big as new gi­ant on the block Vi­a­tris, which launched last month. But size can al­so mean re­dun­dan­cy, and now Vi­a­tris is plot­ting a ma­jor re­struc­tur­ing to stream­line its op­er­a­tions and bot­tom line.

Just weeks af­ter merg­ing two gener­ics gi­ants in My­lan and Pfiz­er’s Up­john unit, new­co Vi­a­tris is gear­ing up for wide-rang­ing cut­backs that could elim­i­nate 20% of the com­bined firms’ glob­al work­force and shut­ter or sell off a clutch of man­u­fac­tur­ing fa­cil­i­ties around the world, ac­cord­ing to up­dat­ed plans Vi­a­tris un­veiled Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER